Patents by Inventor Rodolfo Cadilla

Rodolfo Cadilla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MRGX2 ANTAGONISTS
    Publication number: 20220112174
    Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
    Type: Application
    Filed: October 4, 2021
    Publication date: April 14, 2022
    Inventors: Edward BRNARDIC, Michael BURY, Rodolfo CADILLA, Jon COLLINS, Yu GUO, Anthony HANDLON, Huijie LI, Yue LI, Daniel PAONE, Christie SCHULTE, Barry SHEARER, Guosen YE, Maben YING, Huichang ZHANG
  • Chemical compounds
    Patent number: 11299457
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: April 12, 2022
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Chemical Compounds
    Publication number: 20220009918
    Abstract: A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: November 6, 2019
    Publication date: January 13, 2022
    Inventors: Rodolfo Cadilla, David Norman Deaton, Andrew L. Larkin, Christie Schulte, Terrence L. Smalley
  • CHEMICAL COMPOUNDS
    Publication number: 20210238162
    Abstract: The present invention relates to compounds of Formula (XI): wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 15, 2016
    Publication date: August 5, 2021
    Inventors: Rodolfo CADILLA, David Norman DEATON, Ashley Paul HANCOCK, Heather HOBBS, Simon Teanby HODGSON, Andrew L. LARKIN, Joelle LE, Paul N. MORTENSON, Daniel J. PRICE, Gordon SAXTY, Lee T. SCHALLER, Christie SCHULTE, Ian Edward David SMITH, Stephen Andrew THOMSON, Joseph Wendell WILSON
  • FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS
    Publication number: 20210139507
    Abstract: A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 12, 2018
    Publication date: May 13, 2021
    Inventors: David Norman DEATON, Rodolfo CADILLA
  • CHEMICAL COMPOUNDS
    Publication number: 20200270210
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: May 12, 2020
    Publication date: August 27, 2020
    Inventors: Philip Stewart TURNBULL, Rodolfo Cadilla
  • Chemical compounds
    Patent number: 10710963
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 14, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • CHEMICAL COMPOUNDS
    Publication number: 20190127326
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: December 20, 2018
    Publication date: May 2, 2019
    Inventors: Philip Stewart TURNBULL, Rodolfo CADILLA
  • Chemical compounds
    Patent number: 10196353
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 5, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No 2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • CD38 inhibitors and methods of treatment
    Patent number: 9840496
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 12, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: J. David Becherer, Rodolfo Cadilla, David Norman Deaton, Curt Haffner, Brad Richard Henke, Frank Preugschat, Christie Schulte
  • CD38 INHIBITORS AND METHODS OF TREATMENT
    Publication number: 20170260164
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: September 14, 2017
    Inventors: J. David BECHERER, Rodolfo CADILLA, David Norman DEATON, Curt HAFFNER, Brad Richard HENKE, Frank PREUGSCHAT, Christie SCHULTE
  • Chemical Compounds
    Publication number: 20170073309
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 16, 2017
    Inventors: Philip Stewart TURNBULL, Rodolfo CADILLA
  • Chemical compounds
    Patent number: 9533948
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 3, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • CHEMICAL COMPOUNDS
    Publication number: 20150080449
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: November 20, 2014
    Publication date: March 19, 2015
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Chemical compounds
    Patent number: 8957104
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: February 17, 2015
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
    Publication number: 20140323487
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction
    Patent number: 8822518
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 2, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
    Publication number: 20140100255
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu ZHANG, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Chemical compounds
    Patent number: 8673948
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: March 18, 2014
    Assignee: GlaxoSmithKline, LLC
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla, Andrew Larkin, Huiquiang Zhou, Eugene L. Stewart, Katherine Stetson, Darryl Lynn McDougald, Amarjit Sab Randhawa, John A. Ray
  • CHEMICAL COMPOUNDS
    Publication number: 20140024694
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 23, 2014
    Applicant: GlaxoSmithKline Intellectual Property (No.2) Limit ed
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla